All In Biotech

Drug Trial Radar · NCT01822808

Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure

A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate(HYIS) Versus Placebo on Top of Std Care in African Patients With Acute Heart Failure (AHF) and Left Ventricular Dysfunction

Last checked: Nov 20, 2026Latest source record: Aug 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

500

Planned (sponsor's estimate)

Start

Jan 2013

Primary completion

Jan 2016

Study completion Jul 2016

Sponsor

Lead sponsor
University of Cape TownAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Momentum Research, Inc.
First posted
Apr 2, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the effect of hydralazine isosorbide dinitrate on clinical outcomes, symptoms, cardiac parameters and functional status of African patients hospitalized with AHF and left ventricular dysfunction during 24 weeks of therapy. Administration of hydralazine/nitrates will be superior to placebo administration in reducing HF readmission or death, improving dyspnoea, reducing blood pressure and brain natriuretic peptide (BNP) in African patients admitted with AHF and left ventricular dysfunction.

Conditions

  • Acute Heart Failure
  • Left Ventricular Dysfunction

Interventions

  • HydralazineDrug

    Hydralazine and placebo will be supplied as 25mg identical tablets and given at a dosage of 75mg/day up to week 4, thereafter 150mg/day up to week 24.

  • Isosorbide DinitrateDrug

    Isosorbide dinitrate and placebo will be supplied as 10mg identical tablets and given at a dosage of 30mg/day up to week 4, thereafter 60mg/day up to week 24.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to death or HF re-admissionTime frame: through to day 180

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hatter Institute for Cardiovascular Research in Africa

    Cape Town, Western Cape, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.